Eight companies win medicines automation funding

Eight companies win medicines automation funding

Innovate UK has backed eight new medicines manufacturing automation projects. The £9.3m programme supports robotic laboratories, process data systems and technologies intended to improve the development and production of advanced therapies.


Innovate UK is backing eight UK businesses through a £9.3m investment in digital, automated and robotic technologies for medicines development and manufacturing. The funded projects range from laboratory systems that learn from experimental data to platforms intended to coordinate cell and gene therapy production across connected sites.

The investment forms part of the Transforming Medicines Manufacturing Innovation programme within UK Research and Innovation’s Industrial Strategy life sciences activity. The programme aims to move laboratory processes towards connected instruments, automated handling and analytical systems, with a longer-term ambition to support operation around the clock.

The funded organisations are Allos AI, Astral Neutronics, Danu Insights, FourPlus Immersive, ID Health, Implexis, NunaBio and Ori Biotech. Their proposed technologies cover different manufacturing operations, from chemical formulation and biological processing to synthetic DNA and operator support.

Allos AI is developing an automated laboratory guided by causal artificial intelligence to improve existing medicines while using less drug material. Its concept involves connecting experimentation with models that help select subsequent conditions, rather than relying entirely on a fixed series of manually designed experiments. Whether a system can shorten development depends on the quality of its measurements, the suitability of the tested variables and whether the resulting formulations meet the necessary product specifications.

Astral Neutronics, working with Medicines Discovery Catapult, is developing laboratory processes for radiopharmaceutical manufacturing. These medicines use radioactive materials in diagnosis or treatment, so their production must accommodate specialised handling, process timing, quality controls and relevant radiation protection requirements. The award is intended to help build domestic capability in a technically demanding segment.

Danu Insights is developing a laboratory that can use artificial intelligence to learn from live manufacturing data and refine the production of cell-based cancer therapies. Its partners are the Cell and Gene Therapy Catapult, Lift Therapeutics and Microfluidx. Cells can respond differently to changes in culture conditions and processing, making reliable measurements and controlled process adjustments important if production is to become less dependent on manual intervention.

FourPlus Immersive is working with Exmoor Pharma Concepts on an AI-enabled system that combines wearable technology with production data. The intended application is operator support and reduction of manufacturing errors. It is a different form of automation from a robotic laboratory: information from a production process is made available to personnel performing work, potentially supporting decisions and documentation at the point of operation.

ID Health is developing an integrated platform that combines AI and robotics to make pharmaceutical manufacturing more efficient and support personalised medicines. Implexis is developing an automated platform to design and manufacture medicines intended to be more acceptable to patients receiving cancer treatment. Both projects address the challenge of handling variation in a product or treatment while maintaining controlled manufacturing procedures.

NunaBio’s project concerns a telemetry-enabled platform for synthetic DNA manufacturing. Process telemetry can connect production equipment with records of operating conditions and output, giving engineers evidence on which to assess consistency. Ori Biotech, meanwhile, is working with Adthera Bio and the Cell and Gene Therapy Catapult to demonstrate automated cell and gene therapy production across a network of connected sites rather than relying on a single central manufacturing location.

Each of the projects depends on consistent connections between automated operations, instrument measurements and production records. Robotic handling can move samples, equipment and materials consistently, but medicines manufacture also requires validated process parameters, traceability, contamination controls and testing appropriate to the product. A digital model cannot establish batch quality merely by generating a recommendation; the underlying evidence must support the required manufacturing and regulatory decisions.

Connected systems can also create a practical feedback loop. Instruments record process outcomes, software relates those measurements to operating parameters, and a laboratory may then select another experiment or adjustment. Where the feedback loop controls equipment directly, manufacturers must still establish who can authorise a change, which limits apply and how a deviation is investigated. The eight awards support development of different parts of this wider architecture rather than the deployment of one standard factory solution.

The awards support research and demonstration rather than approval for routine commercial medicines production. Before any system can be incorporated into a regulated production process, its performance and the controls applied to its outputs will require appropriate technical evidence and validation.

The £9.3m total covers eight different routes to medicines manufacturing automation. The 17 November project details do not specify individual award amounts or a common completion date, and the systems remain at different development stages.


Stories for you


  • Eight companies win medicines automation funding

    Eight companies win medicines automation funding

    Innovate UK has backed eight new medicines manufacturing automation projects. The £9.3m programme supports robotic laboratories, process data systems and technologies intended to improve the development and production of advanced therapies.


  • Pulpex secures £19.6m for fibre bottle expansion

    Pulpex secures £19.6m for fibre bottle expansion

    Pulpex has secured £19.6m to expand its fibre bottle business. The fresh National Wealth Fund investment follows the opening of its Glasgow factory in October and supports international manufacturing licences.